Drs. Anish Kirpalani and Darren Yuen, both of St. Michael's Hospital in Toronto, appear to be on the verge of a major practice-changing advance in the assessment of chronic kidney disease. Their study, appearing in cJASN, describes the new methodolog...
Topline results of the Reprise Study in ADPKD have been announced and the good news continues for ADPKD. According to top-line results released by Otsuka, the maker of Tolvaptan:
- Primary and key secondary endpoints were positive for tolvaptan vs. ...
A long awaited analysis of the renal outcomes from the EMPA-REG study was published in the New England Journal of Medicine on June 14th [2]. As originally reported on UKidney, compared to patients taking placebo, the use of empagliflozin was as...
The SPRINT Study was received with great fanfare when it was published on November 26th in the New England Journal of Medicine. The primary results, summarized in the publication’s abstract are these:
"Among patients at high risk for cardiovascular e...
As we continue to process data from the EMPA-REG renal outcomes presentation - which most importantly showed a 46% reduction in the composite of creatinine doubling, end-stage renal disease or renal death - speculation is well underway to explai...
